By Matt Grossman

Abbott Laboratories has gotten an approval from the U.S. Food and Drug Administration for imaging software that uses artificial intelligence to visualize coronary blood flow and blockages.

The Abbott Park, Ill.-based medical-device maker had already received European approval for the technology, an optical coherence tomography imaging platform using Abbott's Ultreon software.

The technology can help doctors improve treatment plans, Abbott said. "As cardiologists continue to adopt OCT and move away from traditional imaging methods such as angiography, emerging technologies are pivotal to determine the best course of patient care," said Dr. Nick West, Abbott's chief medical officer for its vascular business.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

August 03, 2021 09:27 ET (13:27 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Abbott Laboratories Charts.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Abbott Laboratories Charts.